ethyl 6,7-dimethylindole-2-carboxylate | 187753-59-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ethyl 6,7-dimethylindole-2-carboxylate
• 英文别名: 6,7-dimethyl-indole-2-carboxylic acid ethyl ester；6,7-Dimethyl-indol-2-carbonsaeure-aethylester；6,7-dimethyl-1H-indole-2-carboxylic acid ethyl ester；ethyl 6,7-dimethyl-1H-indole-2-carboxylate
• CAS: 187753-59-9
• 化学式: C₁₃H₁₅NO₂
• 分子量: 217.268
• InChiKey: NBKQKNZUPXLSKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  ethyl 6,7-dimethylindole-2-carboxylate 在 喹啉 、 铜 作用下， 生成 6,7-二甲基吲哚
  参考文献：
  名称：

  Marion; Oldfield, Canadian Journal of Research, Section B: Chemical Sciences, 1947, vol. 25, p. 1,12

  摘要：

  DOI：
• 作为产物：
  描述：

  2,3-dimethylphenylhydrazine 在 硫酸 、 zinc(II) chloride 作用下， 生成 ethyl 6,7-dimethylindole-2-carboxylate
  参考文献：
  名称：

  Marion; Oldfield, Canadian Journal of Research, Section B: Chemical Sciences, 1947, vol. 25, p. 1,12

  摘要：

  DOI：

文献信息

• Piperazine derivatives
  申请人：——

  公开号：US20020169163A1

  公开（公告）日：2002-11-14

  Piperazine derivatives, as well as pharmaceutically acceptable salts, solvates and esters thereof, can be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, type II diabetes, obesity and sleep apnoea.

  哌嗪衍生物以及其中医药可接受的盐、溶剂合物和酯，可用于制药制剂的形式，用于治疗或预防中枢神经系统疾病、中枢神经系统损伤、心血管疾病、胃肠疾病、尿崩症、2型糖尿病、肥胖和睡眠呼吸暂停。
• Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles
  申请人：——

  公开号：US20020035110A1

  公开（公告）日：2002-03-21

  The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a] indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R 1 to R 8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.

  本发明涉及1,2,3,4,10,10a,-六氢吡唑[1,2-a]吲哚衍生物以及药用可接受的盐、溶剂合物和酯，其中R1至R8具有如权利要求1中所述的意义，用于以药物制剂的形式治疗或预防中枢神经系统疾病、中枢神经系统损伤、心血管疾病、胃肠疾病、尿崩症、肥胖和睡眠呼吸暂停。
• The Chemistry of 5-Oxodihydroisoxazoles. XVI. A New Synthesis of Pyrroles, Furans, Thiophens and Their Benzo Analogues
  作者：RH Prager、CM Williams

  DOI：10.1071/ch9961315

  日期：——

  Ethyl 5-oxo-2-phenyl-2,5-dihydroisoxazole-4-carboxylate (2) was photolysed at 300 nm in the presence of phenols, enols, anilines, enamines , aryl thiols and thioenols affording enamines. Treatment of these enamines with Lewis or protic acids gives the respective benzo and five- membered ring systems.

  5-氧代-2-苯基-2,5-二氢异噁唑-4-羧酸乙酯（2）在苯酚、烯醇、苯胺、烯胺、芳基硫醇和硫代烯醇存在下于 300 纳米波长下光解，生成烯胺。用路易斯酸或质酸处理这些烯胺，可得到相应的苯并五元环系统。
• [EN] PIPERAZINE DERIVATIVES<br/>[FR] DERIVES DE LA PIPERAZINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2002010169A1

  公开（公告）日：2002-02-07

  The present invention refers to chemical compounds of formula (I) as well as pharmaceutically usable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1. They can be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnoea.

  本发明涉及化学式（I）的化合物，以及其可用于制药的盐，溶剂合物和酯，其中R1至R8具有权利要求1中给出的意义。它们可以用于制药制剂的形式，用于治疗或预防中枢神经系统的疾病，中枢神经系统的损伤，心血管疾病，胃肠疾病，尿崩症，肥胖症和睡眠呼吸暂停。
• Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles
  申请人：Bentley Mark Jonathan

  公开号：US20050239789A1

  公开（公告）日：2005-10-27

  The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a]indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R 1 to R 8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.

  本发明涉及1,2,3,4,10,10a,-六氢吡嗪并[1,2-a]吲哚衍生物，以及其药学上可接受的盐、溶剂和酯，其中R1至R8在权利要求书中所给出的意义下使用，用于制备药物制剂，用于治疗或预防中枢神经系统疾病、中枢神经系统损伤、心血管疾病、胃肠道疾病、尿崩症、肥胖症和睡眠呼吸暂停。